{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:31:47Z","timestamp":1790829107515,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s40262-024-01371-6","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T03:50:51Z","timestamp":1713844251000},"page":"707-719","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Development of a Weight-Band Dosing Approach for Vosoritide in Children with Achondroplasia Using a Population Pharmacokinetic Model"],"prefix":"10.1007","volume":"63","clinical-trial-number":[{"clinical-trial-number":"nct02055157","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02724228","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03197766","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03424018","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03583697","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Yulan","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming Liang","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane R.","family":"Mould","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Larimore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Fisheleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu","family":"Cherukuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Savarirayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melita","family":"Irving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"Bacino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Hoover-Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Ozono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Mohnike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Bober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Henshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,23]]},"reference":[{"key":"1371_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-018-0972-6","volume":"14","author":"RM Pauli","year":"2019","unstructured":"Pauli RM. Achondroplasia: a comprehensive clinical review. Orphanet J Rare Dis. 2019;14:1. https:\/\/doi.org\/10.1186\/s13023-018-0972-6.","journal-title":"Orphanet J Rare Dis"},{"key":"1371_CR2","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s40262-021-01059-1","volume":"61","author":"ML Chan","year":"2022","unstructured":"Chan ML, Qi Y, Larimore K, et al. Pharmacokinetics and exposure-response of vosoritide in children with achondroplasia. Clin Pharmacokinet. 2022;61:263\u201380. https:\/\/doi.org\/10.1007\/s40262-021-01059-1.","journal-title":"Clin Pharmacokinet"},{"key":"1371_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1210\/edrv.21.1.0387","volume":"21","author":"Z Vajo","year":"2000","unstructured":"Vajo Z, Francomano CA, Wilkin DJ. The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: the achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans. Endocr Rev. 2000;21:23\u201339. https:\/\/doi.org\/10.1210\/edrv.21.1.0387.","journal-title":"Endocr Rev"},{"key":"1371_CR4","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1016\/j.gim.2022.08.015","volume":"24","author":"R Savarirayan","year":"2022","unstructured":"Savarirayan R, Irving M, Harmatz P, et al. Growth parameters in children with achondroplasia: a 7-year, prospective, multinational, observational study. Genet Med. 2022;24:2444\u201352. https:\/\/doi.org\/10.1016\/j.gim.2022.08.015.","journal-title":"Genet Med"},{"key":"1371_CR5","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1002\/ajmg.a.61787","volume":"182","author":"PK Foreman","year":"2020","unstructured":"Foreman PK, van Kessel F, van Hoorn R, et al. Birth prevalence of achondroplasia: a systematic literature review and meta-analysis. Am J Med Genet A. 2020;182:2297\u2013316. https:\/\/doi.org\/10.1002\/ajmg.a.61787.","journal-title":"Am J Med Genet A"},{"key":"1371_CR6","doi-asserted-by":"publisher","first-page":"5089","DOI":"10.1242\/jcs.02618","volume":"118","author":"P Krejci","year":"2005","unstructured":"Krejci P, Masri B, Fontaine V, et al. Interaction of fibroblast growth factor and C-natriuretic peptide signaling in regulation of chondrocyte proliferation and extracellular matrix homeostasis. J Cell Sci. 2005;118:5089\u2013100. https:\/\/doi.org\/10.1242\/jcs.02618.","journal-title":"J Cell Sci"},{"key":"1371_CR7","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1038\/s41436-021-01287-7","volume":"23","author":"R Savarirayan","year":"2021","unstructured":"Savarirayan R, Tofts L, Irving M, et al. Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study. Genet Med. 2021;23:2443\u20137. https:\/\/doi.org\/10.1038\/s41436-021-01287-7.","journal-title":"Genet Med"},{"key":"1371_CR8","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1507\/endocrj.k10e-164","volume":"57","author":"A Yasoda","year":"2010","unstructured":"Yasoda A, Nakao K. Translational research of C-type natriuretic peptide (CNP) into skeletal dysplasias. Endocr J. 2010;57:659\u201366. https:\/\/doi.org\/10.1507\/endocrj.k10e-164.","journal-title":"Endocr J"},{"key":"1371_CR9","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/j.joca.2014.07.018","volume":"22","author":"NJ Peake","year":"2014","unstructured":"Peake NJ, Hobbs AJ, Pingguan-Murphy B, et al. Role of C-type natriuretic peptide signalling in maintaining cartilage and bone function. Osteoarthritis Cartil. 2014;22:1800\u20137. https:\/\/doi.org\/10.1016\/j.joca.2014.07.018.","journal-title":"Osteoarthritis Cartil"},{"key":"1371_CR10","unstructured":"Voxzogo. Prescribing information. Novato: BioMarin Pharmaceutical Inc.; 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/214938s002lbl.pdf. Accessed 02 April 2024."},{"key":"1371_CR11","unstructured":"BioMarin Pharmaceutical Australia Pty Ltd. Notice for vosoritide (BioMarin Pharmaceutical Australia Pty Ltd). https:\/\/www.tga.gov.au\/resources\/designations-determinations\/notice-vosoritide-biomarin-pharmaceutical-australia-pty-ltd. Accessed 14 July 2023."},{"key":"1371_CR12","unstructured":"European Medicines Agency. Voxzogo. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/voxzogo-epar-product-information_en.pdf. Accessed 14 July 2023."},{"key":"1371_CR13","unstructured":"BioMarin Pharmaceutical Inc. European Medicines Agency validates application for extension of indication for VOXZOGO\u00ae (vosoritide) for injection to treat children with achondroplasia under the age of 2. News release. January 3, 2023. https:\/\/investors.biomarin.com\/2023-01-03-European-Medicines-Agency-Validates-Application-for-Extension-of-Indication-for-VOXZOGO-R-vosoritide-for-injection-to-Treat-Children-with-Achondroplasia-Under-the-Age-of-2. Accessed 14 July 2023."},{"key":"1371_CR14","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/S0140-6736(20)31541-5","volume":"396","author":"R Savarirayan","year":"2020","unstructured":"Savarirayan R, Tofts L, Irving M, et al. Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial. Lancet. 2020;396:684\u201392. https:\/\/doi.org\/10.1016\/S0140-6736(20)31541-5.","journal-title":"Lancet"},{"key":"1371_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1056\/NEJMoa1813446","volume":"381","author":"R Savarirayan","year":"2019","unstructured":"Savarirayan R, Irving M, Bacino CA, et al. C-type natriuretic peptide analogue therapy in children with achondroplasia. N Engl J Med. 2019;381:25\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1813446.","journal-title":"N Engl J Med"},{"key":"1371_CR16","doi-asserted-by":"publisher","first-page":"1205121","DOI":"10.1155\/2018\/1205121","volume":"2018","author":"AKJ Gradel","year":"2018","unstructured":"Gradel AKJ, Porsgaard T, Lykkesfeldt J, et al. Factors affecting the absorption of subcutaneously administered insulin: effect on variability. J Diabetes Res. 2018;2018:1205121. https:\/\/doi.org\/10.1155\/2018\/1205121.","journal-title":"J Diabetes Res"},{"key":"1371_CR17","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/00005792-199001000-00005","volume":"69","author":"OE Owen","year":"1990","unstructured":"Owen OE, Smalley KJ, D\u2019Alessio DA, et al. Resting metabolic rate and body composition of achondroplastic dwarfs. Medicine (Baltimore). 1990;69:56\u201367. https:\/\/doi.org\/10.1097\/00005792-199001000-00005.","journal-title":"Medicine (Baltimore)"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01371-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-024-01371-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01371-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T17:14:05Z","timestamp":1716225245000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-024-01371-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,23]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["1371"],"URL":"https:\/\/doi.org\/10.1007\/s40262-024-01371-6","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,23]]},"assertion":[{"value":"14 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"These studies were funded by BioMarin Pharmaceutical Inc. Medical writing assistance was provided by Rebecca Lew, PhD, CMPP, and Celine Vivien, PhD, of ProScribe \u2013 Envision Pharma Group, and was funded BioMarin Pharmaceutical Inc. ProScribe\u2019s services complied with international guidelines for Good Publication Practice.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"BioMarin Pharmaceutical Inc. was involved in the study design, data collection, data analysis, and preparation of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Role of the sponsor"}},{"value":"Y.Q., K.L., E.F., A.C., J.D., and J.H.: employees and shareholders of BioMarin Pharmaceutical Inc. M.L.C.: former employee and stockholder of BioMarin Pharmaceutical Inc. D.R.M.: paid consultant for BioMarin Pharmaceutical Inc. R.S. and K.O.: honoraria from BioMarin Pharmaceutical Inc. M.I.: honoraria for consultancy services relating to the subject of this manuscript. C.A.B. and K.M.: no conflicts of interest. J.H.-.F.: institution received funding from BioMarin Pharmaceutical Inc. to execute the study presented in this manuscript. Funds were also received from Pfizer and QED for other achondroplasia-related studies. J.H.-F.: consultant for BioMarin Pharmaceutical Inc., Pfizer, QED, and Sanofi, related to achondroplasia. W.R.W.: local principal investigator for the vosoritide studies at Emory University, funded by a clinical trial contract from BioMarin Pharmaceutical Inc. to Emory University. W.R.W. received honoraria for advisory committee meetings from BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. paid for writing assistance for the manuscript. M.B.B.: employed by the Nemours Foundation, which has received institutional support for research from Ascendis Pharma, BioMarin Pharmaceutical Inc., QED, and Therachon\/Pfizer. His institution has received consulting fees from BioMarin Pharmaceutical Inc. and Tyra Biosciences. M.B.B. has received consulting fees from Ascendis Pharma, BioMarin Pharmaceutical Inc., QED, and Therachon\/Pfizer. He has received compensation for speaking on behalf of the Alexion speaker\u2019s bureau and from Novo Nordisk and Tyra Biosciences. In the future, he will be employed by Tyra Biosciences.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The de-identified individual participant data that underlie the results reported in this article (including text, tables, figures, and appendixes) will be made available together with the research protocol and data dictionaries, for non-commercial, academic purposes. Additional supporting documents may be available on request. Investigators will be able to request access to these data, along with supporting documents, via a website beginning at 6 months and ending 2 years after publication. Data associated with any ongoing development program will be made available within 6 months after approval of the relevant product. Requests must include a research proposal clarifying how the data will be used, including proposed analysis methodology. Research proposals will be evaluated relative to publicly available criteria at the BioMarin website to determine whether access will be given, contingent on execution of a data access agreement with BioMarin Pharmaceutical. For data access requests, see .","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"The ethical principles outlined in the Declaration of Helsinki, the US Code of Federal Regulations, and the International Conference on Harmonisation Guideline for Good Clinical Practice E6 were followed during the conduct of the study. The study protocols were approved by relevant ethics review boards and informed consent was obtained from all parents or guardians in writing.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all parents or guardians in writing.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Y.Q., M.L.C., and J.H. contributed to the conceptualization of the study. Y.Q., E.F., A.C., and J.D. curated the data. Y.Q., D.R.M., and A.C. conducted formal analysis. J.D., R.S., M.I., J.H.-F., K.M., W.R.W., and M.B.B. contributed to the investigation. Y.Q., M.L.C., K.L., C.A.B., and J.H. contributed to the methodology. Y.Q. and M.L.C. took on project administration. Y.Q., M.L.C., K.O., W.R.W., and J.H. provided supervision. K.L. oversaw bioanalytical method development, validation, and sample testing. Y.Q., M.L.C., and D.R.M. were responsible for visualizing the data. All authors provided meaningful and substantial edits and critically reviewed\/approved the final version of the manuscript.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}